| Literature DB >> 24090456 |
Hong-ying Gao1, Guo-yu Li, Jian Huang, Ying Han, Fu-zhou Sun, Xiao-wei Du, Li-juan An, Hang-yu Wang, Jin-hui Wang.
Abstract
BACKGROUND: Zhuyeqing Liquor (ZYQL), a well-known Chinese traditional health liquor, has various biological properties, including anti-oxidant, anti-inflammatory, immunoenhancement and cardiovascular protective effects.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24090456 PMCID: PMC3852147 DOI: 10.1186/1472-6882-13-252
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Effect of ZYQL on organ coefficient in normal and immunosuppressed mice
| Normal control | 4.57±0.38 | 0.26±0.10 | 0.16±0.05 |
| Cy(100 mg/kg) | 4.80±0.45 | 0.21±0.06# | 0.04±0.01## |
| ZYQL-A(100 mg/kg) | 4.32±0.63 | 0.29±0.10 | 0.17±0.05 |
| ZYQL-B(200 mg/kg) | 4.39±0.25 | 0.31±0.06 | 0.15±0.03 |
| ZYQL-C(400 mg/kg) | 4.41±0.48 | 0.27±0.07 | 0.15±0.01 |
| ZYQL-A(100 mg/kg)+Cy | 4.02±0.21 | 0.25±0.05 | 0.12±0.02** |
| ZYQL-B(200 mg/kg)+Cy | 4.28±0.56 | 0.27±0.03* | 0.13±0.03** |
| ZYQL-C(400 mg/kg)+Cy | 4.38±0.40 | 0.27±0.04* | 0.13±0.04** |
Data is expressed as the mean±SD (n = 10).
## Significant difference at p<0.01 levels compared with normal control group.
# Significant difference at p<0.05 levels compared with normal control group.
** Significant difference at p<0.01 levels compared with Cy-treated group.
* Significant difference at p<0.05 levels compared with Cy-treated group.
Effect of ZYQL on phagocytotic function of mononuclear phagocytic system
| Normal control | 1.65±0.15 | 3.87±0.74 |
| Cy(100 mg/kg) | 1.18±0.14## | 3.04±0.65## |
| ZYQL-A(100 mg/kg) | 1.70±0.13 | 3.99±0.91 |
| ZYQL-B(200 mg/kg) | 1.80±0.16 | 4.23±0.98 |
| ZYQL-C(400 mg/kg) | 1.85±0.21 | 4.35±0.87# |
| ZYQL-A(100 mg/kg)+Cy | 1.43±0.15 | 3.69±0.46* |
| ZYQL-B(200 mg/kg)+Cy | 1.64±0.18* | 3.97±0.58* |
| ZYQL-C(400 mg/kg)+Cy | 1.72±0.16* | 4.11±0.62** |
Data is expressed as the mean±SD (n = 10).
a g.
b Carbon clearance index.
## Significant difference at p<0.01 levels compared with normal control group.
# Significant difference at p<0.05 levels compared with normal control group.
** Significant difference at p<0.01 levels compared with Cy-treated group.
* Significant difference at p<0.05 levels compared with Cy-treated group.
Effect of ZYQL on cytokine secretion levels and LSZ in normal and immunosuppressed mice
| Normal control | 74.47±15.12 | 246.44±32.62 | 6.31±0.98 |
| Cy(100 mg/kg) | 40.56±9.76## | 80.96±10.83## | 3.87±0.67## |
| ZYQL-A(100 mg/kg) | 81.60±24.82 | 262.52±55.74 | 7.03±1.05 |
| ZYQL-B(200 mg/kg) | 89.04±15.57 | 277.61±68.42 | 7.67±1.12## |
| ZYQL-C(400 mg/kg) | 86.98±11.97 | 256.81±46.83 | 7.30±0.91# |
| ZYQL-A(100 mg/kg)+Cy | 80.54±11.37** | 185.34±28.81** | 4.57±0.85* |
| ZYQL-B(200 mg/kg)+Cy | 101.74±30.72** | 231.84±58.32** | 8.87±0.76** |
| ZYQL-C(400 mg/kg)+Cy | 79.24±16.66** | 230.16±31.63** | 7.98±0.98** |
Data is expressed as the mean±SD (n = 10).
a pg/mL.
b pg/mL.
c μg/mL.
## Significant difference at p<0.01 levels compared with normal control group.
# Significant difference at p<0.05 levels compared with normal control group.
** Significant difference at p<0.01 levels compared with Cy-treated group.
* Significant difference at p<0.05 levels compared with Cy-treated group.
∆ Significant difference at p<0.05 (fIFN-γ = 3.692, fLSZ = 3.845) levels compared between cyclophosphamide- untreated groups and cyclophosphamide-treated groups (two-way ANOVA followed by LSD’s test).
Effect of ZYQL on spleen antioxidant enzyme activities in normal and immunosuppressd mice
| Normal control | 1029.23±79.08 | 30.28±2.91 | 103.07±5.52 |
| Cy(100 mg/kg) | 566.53±26.56## | 17.23±1.48## | 54.66±9.61## |
| ZYQL-A(100 mg/kg) | 1097.86±96.38 | 33.87±1.05 | 106.14±14.07 |
| ZYQL-B(200 mg/kg) | 1181.81±44.51## | 45.02±6.00## | 131.75±37.18## |
| ZYQL-C(400 mg/kg) | 1167.57±39.34## | 42.96±6.94## | 140.00±20.25## |
| ZYQL-A(100 mg/kg)+Cy | 646.71±42.88* | 19.85±1.65** | 79.16±12.69** |
| ZYQL-B(200 mg/kg)+Cy | 724.57±56.51** | 23.57±0.66** | 87.46±9.54** |
| ZYQL-C(400 mg/kg)+Cy | 722.08±112.92** | 20.24±1.30** | 81.66±10.26** |
Data is expressed as the mean±SD (n = 10).
a μmol/g protein.
b U/mg protein.
c U/mg protein.
## Significant difference at p<0.01 levels compared with normal control group.
** Significant difference at p<0.01 levels compared with Cy-treated group.
* Significant difference at p<0.05 levels compared with Cy-treated group.
∆ Significant difference at p<0.05 (fCAT = 9.476, fSOD = 2.613) levels compared between cyclophosphamide-untreated groups and cyclophosphamide-treated groups (two-way ANOVA followed by LSD’s test).